{"id":"NCT04571060","sponsor":"Pfizer","briefTitle":"Randomized Trial in Adult Participants With Acute Migraines","officialTitle":"Double-Blind, Randomized, Placebo-controlled, Safety and Efficacy Trial of BHV-3500 (Zavegepant) Intranasal for the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-27","primaryCompletion":"2021-10-10","completion":"2021-10-22","firstPosted":"2020-09-30","resultsPosted":"2023-03-16","lastUpdate":"2023-04-24"},"enrollment":1978,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Zavegepant","otherNames":["BHV3500"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Zavegepant","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.","primaryOutcome":{"measure":"Percentage of Participants With Freedom From Pain at 2 Hours Post-dose","timeFrame":"2 hours post-dose","effectByArm":[{"arm":"Zavegepant 10 mg","deltaMin":23.6,"sd":null},{"arm":"Placebo","deltaMin":14.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":94,"countries":["United States"]},"refs":{"pmids":["36804093"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":629},"commonTop":["Dysgeusia"]}}